PUBLIC COMPANY
saveBlueprint Medicines Corp
updated 12d ago
community read0 votes
pipeline
4
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 32Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- phase3(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- —An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
- phase2Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
- phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- —A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
- —Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- phase1A Study of Elenestinib in Healthy Adult Female Participants
🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that